Anticancer Inhibitors

The word "cancer" is associated with at least 100 different pathologies, depending on the organ involved and the type of tumor developed. Cancer is a complex disease involving multiple pathogenetic mechanisms. Characterization of different types of cancers, which distinguishes them from he...

Full description

Saved in:
Bibliographic Details
HerausgeberIn:
Sonstige:
Year of Publication:2022
Language:English
Physical Description:1 electronic resource (216 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 04429nam-a2201225z--4500
001 993560435804498
005 20240124163300.0
006 m o d
007 cr|mn|---annan
008 202209s2022 xx |||||o ||| 0|eng d
035 |a (CKB)5680000000080839 
035 |a (oapen)https://directory.doabooks.org/handle/20.500.12854/92104 
035 |a (EXLCZ)995680000000080839 
041 0 |a eng 
100 1 |a Fantacuzzi, Marialuigia  |4 edt 
245 1 0 |a Anticancer Inhibitors 
260 |a Basel  |b MDPI Books  |c 2022 
300 |a 1 electronic resource (216 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
506 |a Open access  |f Unrestricted online access  |2 star 
520 |a The word "cancer" is associated with at least 100 different pathologies, depending on the organ involved and the type of tumor developed. Cancer is a complex disease involving multiple pathogenetic mechanisms. Characterization of different types of cancers, which distinguishes them from healthy cells and other cancers, allows for the identification of specific targets for each individual tumor. The principle of chemotherapy is based on interference with the mechanisms that regulate the life and proliferation of cancer cells, causing their death. In recent years, there has been continuous progress in the development of therapeutic agents against cancer, which is ongoing.The Anticancer Inhibitors Special Issue focuses on new target-based anticancer agents that inhibit a specific target involved in the suppression of various types of cancer and the control of their chemoresistance.There is a collection of research and review articles on advances in drug discovery, design, and development of new inhibitor compounds with potency against various cancer types. 
546 |a English 
650 7 |a Research & information: general  |2 bicssc 
650 7 |a Chemistry  |2 bicssc 
653 |a breast cancer 
653 |a tamoxifen 
653 |a LY294002 
653 |a synergism 
653 |a apoptosis 
653 |a cell cycle 
653 |a tea (Camellia sinensis) flowers 
653 |a BTFS 
653 |a A2780/CP70 ovarian cancer cells 
653 |a S phase cell cycle arrest 
653 |a nicotinamide phosphoribosyltransferase 
653 |a NAD+ biosynthesis 
653 |a inhibitor 
653 |a azacyclohexane 
653 |a anticancer drug 
653 |a drug design 
653 |a enthalpy effect 
653 |a NSCLC 
653 |a Cathepsin K 
653 |a cell proliferation 
653 |a cell migration 
653 |a cell invasion 
653 |a mTOR 
653 |a isatin-hydrazones 
653 |a cytotoxicity 
653 |a CDK2 inhibitor 
653 |a ATP competitive inhibitor 
653 |a ADME analysis 
653 |a receptor tyrosine kinases 
653 |a protein-protein interactions 
653 |a protein engineering 
653 |a directed evolution 
653 |a angiogenesis 
653 |a binding affinity 
653 |a agonistic activity 
653 |a saponins 
653 |a phytochemicals 
653 |a tea (Camellia sinensis) flower 
653 |a ovarian cancer 
653 |a autophagy 
653 |a ZMYND8 
653 |a tumorigenesis 
653 |a epigenetic regulation 
653 |a pro-oncogenic effects 
653 |a tumor suppression 
653 |a tacrine-coumarin derivatives 
653 |a DNA 
653 |a topoisomerases I, II 
653 |a lung carcinoma cells 
653 |a A549 
653 |a chemotherapy 
653 |a prodrug 
653 |a drug targeting 
653 |a overexpressed enzymes 
653 |a ADC 
653 |a ADEPT 
653 |a GDEPT 
653 |a LEAPT 
653 |a PROTAC 
653 |a cyclin-dependent kinase 
653 |a cancer 
653 |a resistance 
653 |a small molecule inhibitors 
653 |a PROTACs 
653 |a statins 
653 |a pancreatic cancer 
653 |a DNA microarray 
653 |a pitavastatin 
653 |a cerivastatin 
653 |a simvastatin 
653 |a fluvastatin 
653 |a atorvastatin 
653 |a pravastatin 
653 |a HMG-CoA reductase inhibitors 
776 |z 3-0365-4920-X 
776 |z 3-0365-4919-6 
700 1 |a Ammazzalorso, Alessandra  |4 edt 
700 1 |a Fantacuzzi, Marialuigia  |4 oth 
700 1 |a Ammazzalorso, Alessandra  |4 oth 
906 |a BOOK 
ADM |b 2024-01-25 02:20:51 Europe/Vienna  |f system  |c marc21  |a 2022-09-22 08:09:39 Europe/Vienna  |g false 
AVE |i DOAB Directory of Open Access Books  |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5344130510004498&Force_direct=true  |Z 5344130510004498  |b Available  |8 5344130510004498